239 related articles for article (PubMed ID: 30670815)
1. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
[TBL] [Abstract][Full Text] [Related]
2. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
4. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
Zhu L; Yu CL; Zheng Y
Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
[TBL] [Abstract][Full Text] [Related]
5. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
7. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
Ding L; Xie Z
Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
9. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
[TBL] [Abstract][Full Text] [Related]
10. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
[TBL] [Abstract][Full Text] [Related]
11. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
[TBL] [Abstract][Full Text] [Related]
12. BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation.
Fu W; Sun H; Zhao Y; Chen M; Yang X; Liu Y; Jin W
Theranostics; 2019; 9(22):6468-6484. PubMed ID: 31588230
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
[TBL] [Abstract][Full Text] [Related]
15. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
17. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
18. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
19. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
20. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
